Loading PODD detail
Loading ticker data...
Loading PODD detail
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia.
Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Chart data unavailable
NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Pre-Market Stock Futures: Futures are trading lower on Tuesday morning after investors returned from the three-day Easter weekend to find a stock market ready to rally after some promising news on the war in Iran and a sense, among some across the financial world, that the market had put in a new bottom. Ed Yardeni,... Here Are Tuesday's Top Wall Street Analyst Research Calls: Ameriprise Financial, Arista Networks, Arm Holdings, Lennar, Morgan Stanley, Rocket Lab, Tractor Supply, Wingstop, Wix.com and More
New York, New York--(Newsfile Corp. - April 6, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation (NASDAQ: PODD) ("Insulet Corporation") concerning potential violations of the federal securities laws. During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2 users in 2025.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Insulet Corp. Stock Falls After Voluntary Medical Device Correction Reveals Omnipod 5 Insulin-Leakage Defect Affecting Thousands of Pods NEW YORK, April 1, 2026 /PRNewswire/ -- Insulet Corp. (NASDAQ: PODD) shares dropped approximately 6.9% after the Company filed an 8-K on March 12, 2026, disclosing a voluntary medical device correction covering Omnipod 5 insulin pods due to a design defect that could cause insulin leakage -- a defect linked to eighteen serious adverse events. Shareholders who lost money on their PODD investment are encouraged to submit their information here.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Inves.
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Appoints Mike Panos as Chief Commercial Officer.
SG Americas Securities LLC lifted its position in shares of Insulet Corporation (NASDAQ: PODD) by 1,359.0% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,261 shares of the medical instruments supplier's stock after purchasing an additional 36,570 shares during the period.
Beacon Investment Advisory Services Inc. decreased its holdings in Insulet Corporation (NASDAQ: PODD) by 11.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 71,950 shares of the medical instruments supplier's stock after selling 9,390 shares during the quarter. Beacon Investment Advisory Services
New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Insulet Corporation ("Insulet Corporation") (NASDAQ: PODD) concerning potential violations of the federal securities laws. During that same February 18 earnings call, McEvoy stated that "strong clinical evidence and real-world outcomes continue to earn prescriber and patient confidence" and described Omnipod 5 as the "favorite pump" for both type-1 and type-2 users in 2025.
LOS ANGELES--(BUSINESS WIRE)---- $PODD--PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm.
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
